Teleflex faces potential impairment charges for its Interventional Urology North America reporting unit due to lower-than-expected UroLift sales and macroeconomic factors. Significant restructuring charges are anticipated from the 2024 Footprint realignment plan, with potential cash outlays of $31-$38 million. Uncertainties exist regarding environmental liabilities, legal proceedings, and the Italian payback measure, which could lead to increased costs. Customer inventory management could negatively impact future OEM segment sales.

Read More

Teleflex anticipates achieving annual pre-tax savings of $12-$14 million from the 2024 Footprint realignment plan. The company expects to realize plan-related savings in 2024. The acquisition of Palette Life Sciences AB could contribute to revenue growth. Increased sales of new products and price increases are expected to drive revenue growth.

Read More